Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706697 | 1.00 | GSK3B (0.54) | GSK3BABCG2MAOBTDP1LMNA | |
| Cyclohexylamine SCHEMBL7802679 | 0.83 | GSK3B (0.43) | GSK3BABCG2MAOBTDP1LMNA | |
| SCHEMBL8489579 | 0.83 | KDM4E (0.70) | GSK3BMAOBHSD17B10KDM4EMAPT | |
| SCHEMBL8489573 | 0.83 | KDM4E (0.70) | GSK3BMAOBHSD17B10KDM4EMAPT | |
| SCHEMBL1403601 | 0.83 | MAOB (0.48) | GSK3BABCG2MAOBTDP1LMNA | |
| SCHEMBL1403602 | 0.83 | MAOB (0.48) | GSK3BABCG2MAOBTDP1LMNA | |
| SCHEMBL1012582 | 0.83 | KDM4E (0.61) | GSK3BTDP1LMNAKMT2AMEN1 | |
| SCHEMBL6852501 | 0.81 | TDP1 (0.46) | GSK3BTDP1LMNAKMT2AMEN1 | |
| SCHEMBL4803778 | 0.81 | GSK3B (0.49) | GSK3BABCG2MAOBTDP1LMNA | |
| SCHEMBL438892 | 0.81 | GSK3B (0.49) | GSK3BABCG2MAOBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024139373-A1 | METHOD FOR SYNTHESIZING FLUDIOXONIL INTERMEDIATE 2,2-DIFLUORO-1,3-BENZODIOXOLE-4-FORMALDEHYDE | 淮北师范大学 | 2024-07-04 | — | — | WO | claimed |
| CN-117567486-A | Tridentate copper complex with high chemical nuclease activity and preparation method thereof | 南华大学 | 2024-02-20 | — | — | CN | claimed |
| CN-114907308-B | Refining method of 3, 4-methylenedioxy benzaldehyde | 河北海力恒远新材料股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | claimed |
| CN-114057723-B | Synthesis method of 13-methyl berberine alkaloid | 四川大学 | 2023-05-26 | — | — | CN | claimed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | claimed |
| CN-114907308-A | Refining method of 3, 4-methylenedioxybenzaldehyde | 河北海力香料股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-114057723-A | Synthetic method of 13-methyl berberine alkaloid | 四川大学 | 2022-02-18 | — | — | CN | claimed |
| EP-2809760-B1 | PROCESS FOR REDUCING MALODOURS | HENKEL AG & CO KGAA (DE) | 2019-03-20 | — | — | EP | claimed |
| CN-108349930-A | Substituted Tricycles and Methods of Use | 艾伯维公司 | 2018-07-31 | — | — | CN | claimed |
| EP-0931083-A4 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | HARVARD COLLEGE (US) | 2000-05-24 | — | — | EP | claimed |
| EP-0931083-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998012198-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-26 | — | — | WO | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0302980-B1 | 1,4-DIHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | LABORATORIOS DELAGRANGE S.A. (ES) | 1991-03-13 | — | — | EP | claimed |
| CN-1031531-A | 1,4-dihydropyridine its preparation method and be used for the purposes of medicine | DELAGRANGE LAB (ES) | 1989-03-08 | — | — | CN | claimed |
| EP-0302980-A1 | 1,4-Dihydropyridines, process for their preparation and their use as medicaments | LABORATORIOS DELAGRANGE S.A. (ES) | 1989-02-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | GSK3B 2241/4885ABCG2 17/4885MAOB 3977/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | GSK3B 2332/4885ABCG2 17/4885MAOB 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.